Free Trial

Canopy Growth (NASDAQ:CGC) Stock Rating Lowered by Wall Street Zen

Canopy Growth logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Wall Street Zen downgraded Canopy Growth from “hold” to “sell,” while the broader analyst consensus remains “Hold,” with two Buy, two Hold and one Sell rating.
  • CGC shares opened at $0.71, near their one-year low of $0.69, and are down 3.1%; the company has a market capitalization of approximately $320 million and remains unprofitable.
  • Canopy Growth exceeded quarterly expectations, reporting an adjusted loss of $0.02 per share versus the anticipated $0.04 loss and revenue of $142.62 million versus estimates of $58.21 million.
  • MarketBeat previews top five stocks to own in November.

Canopy Growth (NASDAQ:CGC - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a "hold" rating to a "sell" rating in a research report issued on Saturday, Wall Street Zen reports.

Separately, Weiss Ratings raised shares of Canopy Growth from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Friday, October 2nd. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Hold".

Check Out Our Latest Research Report on CGC

Canopy Growth Stock Down 3.1%

CGC opened at $0.71 on Friday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 2.39 and a current ratio of 3.04. Canopy Growth has a 1 year low of $0.69 and a 1 year high of $2.38. The firm has a 50 day moving average price of $0.94 and a 200 day moving average price of $0.99. The company has a market cap of $320.35 million, a PE ratio of -1.58 and a beta of 0.78.

Canopy Growth (NASDAQ:CGC - Get Free Report) last released its quarterly earnings data on Friday, August 7th. The company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.04) by $0.02. The company had revenue of $142.62 million for the quarter, compared to analyst estimates of $58.21 million. Canopy Growth had a negative return on equity of 21.91% and a negative net margin of 65.33%. Sell-side analysts expect that Canopy Growth will post -0.10 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Royal Bank of Canada grew its stake in shares of Canopy Growth by 1,115.6% in the 1st quarter. Royal Bank of Canada now owns 975,967 shares of the company's stock worth $927,000 after purchasing an additional 895,680 shares during the last quarter. Lazard Asset Management LLC purchased a new stake in Canopy Growth during the first quarter valued at about $1,716,000. Finally, Caitong International Asset Management Co. Ltd increased its position in shares of Canopy Growth by 723.5% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 4,595,330 shares of the company's stock worth $5,239,000 after acquiring an additional 4,037,281 shares in the last quarter. Institutional investors and hedge funds own 3.33% of the company's stock.

About Canopy Growth

(Get Free Report)

Canopy Growth Corporation is a cannabis company headquartered in Smiths Falls, Ontario. Founded in 2013 as Tweed Marijuana Inc, the company adopted the Canopy Growth name in 2015 and became one of Canada's early large-scale licensed cannabis producers.

Canopy Growth develops, produces, distributes and sells cannabis products for the Canadian medical and adult-use markets. Its offerings include dried flower, pre-rolls, oils, softgels, vapes, beverages and edibles marketed under brands such as Tweed, 7ACRES, DOJA and Deep Space.

Further Reading

Analyst Recommendations for Canopy Growth (NASDAQ:CGC)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Canopy Growth Right Now?

Before you consider Canopy Growth, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Canopy Growth wasn't on the list.

While Canopy Growth currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines